Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ondansetron Injection Generic Name & Formulations
Legal Class
Rx
General Description
Ondansetron (as HCl dihydrate) 2mg/mL; IV or IM inj.
Pharmacological Class
Selective 5-HT3 receptor antagonist.
See Also
How Supplied
Tabs 4mg, 8mg—30; ODT 4mg, 8mg—30; Oral soln—50mL, vials—contact supplier
Manufacturer
Generic Availability
YES
Ondansetron Injection Indications
Indications
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Prevention of post-op nausea and vomiting.
Ondansetron Injection Dosage and Administration
Adult
Chemotherapy (vials must be diluted; see full labeling): >18yrs: Infuse over 15 mins. 0.15mg/kg (max 16mg/dose) IV every 4hrs for 3 doses beginning 30 mins before chemotherapy. Severe hepatic dysfunction: max 8mg/day. Post-op (do not dilute): Infuse in not less than 30 seconds, preferably over 2–5 mins: 4mg IV as single dose immediately before induction of anesthesia; or shortly post-op if nausea or vomiting occurs. Or, may use 4mg IM undiluted as a single injection.
Children
Chemotherapy (vials must be diluted; see full labeling): Infuse over 15 mins. <6 months: see full labeling. 6 months–18yrs: 0.15mg/kg (max 16mg/dose) IV for 3 doses every 4hrs beginning 30 mins before chemotherapy. Post-op (do not dilute): Infuse in not less than 30 seconds, preferably over 2–5 mins: <1 month: see full labeling. 1 month–12yrs (<40kg): 0.1mg/kg. ≥40kg: 4mg. Give IV as single dose immediately before induction of anesthesia; or shortly post-op if nausea or vomiting occurs.
Ondansetron Injection Contraindications
Contraindications
Concomitant apomorphine.
Ondansetron Injection Boxed Warnings
Not Applicable
Ondansetron Injection Warnings/Precautions
Warnings/Precautions
<4 months of age (monitor closely). Not a substitute for nasogastric suction in gastric or intestinal peristalsis. Congenital long QT syndrome: avoid. Electrolyte abnormalities, CHF, bradyarrhythmias, concomitant drugs that prolong QT: monitor ECG. May mask progressive ileus and/or gastric distention. GI obstruction risk: monitor for decreased bowel activity. Coronary artery spasm. Monitor for myocardial ischemia during and after administration (esp. IV use; do not exceed recommended infusion rate). Phenylketonuria (ODT form). Hepatic dysfunction. Pregnancy. Nursing mothers.
Ondansetron Injection Pharmacokinetics
See Literature
Ondansetron Injection Interactions
Interactions
See Contraindications. Profound hypotension, loss of consciousness with apomorphine. Serotonin syndrome possible esp. with concomitant serotonergic drugs (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue). May antagonize tramadol.
Ondansetron Injection Adverse Reactions
Adverse Reactions
Diarrhea, headache, fever, constipation, fatigue, transient blindness; serotonin syndrome (discontinue if occurs); rare: angina, bronchospasm, anaphylaxis, seizures, ECG changes (including QT prolongation).
Ondansetron Injection Clinical Trials
See Literature
Ondansetron Injection Note
Not Applicable
Ondansetron Injection Patient Counseling
See Literature
